Special Session

CB 01 - Cancer Breakthroughs - Takeaways from the Major Oncology Meetings of 2019

9/18/2019
9:15 AM - 11:00 AM
Location: Room W375 a/b/c/d

Session Type: Special Session
1.75 AMA PRA Category 1 Credits™
1.75 CAMPEP Credits
2.00 MDCB Credits

In collaboration with four of the major oncology associations, this session will highlight the most important breakthroughs in cancer research in 2019. ASCO, AACR, AAPM and RRS have joined with ASTRO to provide this exciting new "can't miss" session!

Scientific Review from ASCO - Lori Pierce, MD

-Abstract LBA1008: Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2- advanced breast cancer (ABC) treated with endocrine therapy ? ribociclib: Overall survival (OS) results. (Sara A. Hurvitz)

-Abstract 9500: Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs). (Gerald Fogarty)


Scientific Review from AACR - Robert Den, MD

-A Dose Escalation Trial of the Wee1 Inhibitor AZD1775, in Combination with Gemcitabine and Radiation for Patients with Locally Advanced Pancreatic Cancer

-Identifying Molecular Determinants of Response to Apalutamide in Patients with Nonmetastatic Castration-resistant Prostate Cancer in the SPARTAN Study


Scientific Review from AAPM - Kristy Brock, PhD

-Multiparametric Breast MRI Radiomics in Distinguishing Between Benign and Malignant Breast Lesions
Q Hu1*, H Whitney1,2 , A Edwards1 , J Papaioannou1 , M Giger1 , (1) University of Chicago, Chicago, IL, (2) Wheaton College, Wheaton, IL (AAPM Annual Meeting Presentation,https://w3.aapm.org/meetings/2019AM/programInfo/programAbs.php?sid=8160&aid=44207)

-First human imaging studies with the EXPLORER total-body PET scanner. Journal of Nuclear Medicine. 2019 Mar 1;60(3):299-303. Badawi RD, Shi H, Hu P, Chen S, Xu T, Price PM, Ding Y, Spencer BA, Nardo L, Liu W, Bao J.

Scientific Review from RRS - David Kirsch, MD, PhD, FASTRO

-FLASH-Radiation Therapy (Ultra-high dose rate) protects normal tissue without compromising tumor control: mechanisms and clinical perspectives
Marie-Catherine Vozenin, The Centre Hospitalier Universitaire Vaudois-d?partement d'Oncologie, Lausanne, Switzerland

-Dissecting Mechanisms of Response and Resistance to Radiation and Immunotherapy
Amy J. Wisdom; Yvonne M. Mowery, MD, PhD; Cierra Hong, BS; Chelsae R. Dumbauld, BS; David J. Carpenter, MD; Kathleen A. Ashcraft, PhD; Collin L. Kent, MD; Nerissa Williams; Anupama Reddy, PhD; Lorraine D. Campos; Yan Ma; Sandeep S. Dave, MD, MBA, MS; Kent J. Weinhold, PhD; and David G. Kirsch, MD, PhD
Duke University, Durham, NC

Learning Objectives:

Presentations:

Lisa Kachnic, MD, FASTRO

Columbia University Radiation Oncology

Disclosure:
Employment
Vanderbilt University Medical Center: Chair Radiation Oncology: Employee

Leadership
ABR: President: President

Biography:
Lisa Kachnic, MD, FASTRO, is professor and Chairperson of the Radiation Oncology Department at the Columbia University Medical Center in New York, NY. She received her undergraduate degree from Boston College, her medical degree from Tufts University, and completed her residency in radiation oncology at Harvard University, with her last year as chief resident.

Dr Kachnic’s primary areas of interest include rectal and anal malignancies, image-guided radiation delivery, and outcomes/symptoms management research. She is actively involved in the National Cancer Institute’s (NCI) adult oncology research cooperative groups. She is also the GI radiation oncology chairperson and anorectal co-chairperson for SWOG, where she also serves as the multimodality executive officer. Importantly, her NCI clinical trials have changed the standard of care in several GI malignancies, most notably anal cancer. As a tribute to these leadership efforts, she has been awarded NCI funding from NRG and SWOG, and was the 2008 recipient of the first Radiation Therapy Oncology Group’s “Next Generation Investigator” award.

Dr Kachnic belongs to a number of professional organizations including the American Society of Radiation Oncology (ASTRO), the American Board of Radiology (ABR), and the American Society of Clinical Oncology (ASCO). She serves on the editorial boards of the Journal of the National Cancer Institute and Gastrointestinal Cancer Research. She has other national leadership positions that are worthy of mention. She recently became a fellow of ASTRO after many years of service, most recently as Scientific Committee chair. She is a member of the NCI Intergroup Rectal-Anal Cancer Task Force, and was the chairperson for the 2014 ASCO GI meeting. After several years as chairperson of the ABR radiation oncology exams in GI cancers, she became the radiation oncology GI trustee for the ABR in 2010, and ABR Board of Governor and President in 2016.

Presentation(s):

Send Email for Lisa Kachnic

Theodore DeWeese, MD, FASTRO

Johns Hopkins School of Medicine

Disclosure:
Employment
Johns Hopkins University: Professor and Chair: Employee

Presentation(s):

Send Email for Theodore DeWeese


Assets

CB 01 - Cancer Breakthroughs - Takeaways from the Major Oncology Meetings of 2019



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for CB 01 - Cancer Breakthroughs - Takeaways from the Major Oncology Meetings of 2019